Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin
| Autor: | M. E. R. O'brien, I. E. Smith, M. E. Gore, Shiranee Sriskandan, Peter Collins |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Cardiomyopathy
Dilated Cardiac function curve medicine.medical_specialty Lymphoma B-Cell Adolescent Heart disease medicine.medical_treatment Cardiomyopathy Drug Administration Schedule Internal medicine medicine Humans Rhabdomyosarcoma Embryonal Doxorubicin Rhabdomyosarcoma Heart transplantation Dose-Response Relationship Drug business.industry General Medicine Middle Aged medicine.disease Surgery Transplantation Toxicity cardiovascular system Cardiology Heart Transplantation Female business Research Article medicine.drug |
| Zdroj: | Postgraduate Medical Journal. 70:759-761 |
| ISSN: | 1469-0756 0032-5473 |
| DOI: | 10.1136/pgmj.70.828.759 |
| Popis: | Summary There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure. It is generally thought that doses below 500-550 mg/m2 are safe but, when objective measures of cardiac function are used, it becomes apparent that degrees of cardiac failure occur at doses below this. We present here the case histories of two patients who developed very severe cardiac failure at cumulative doses well below 500 mg/m2 but who survived their initial cardiac illness due to aggressive intervention. In one case, the patient was successfully treated by orthotopic cardiac transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|